The Lancet publishes Capricor's phase 3 DMD therapy trial results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy
July 29, 2026 10:05 AM EDT--Independent Peer Review Provides External Validation of the Trial's Design, Statistical Methodology and Findings--
--Randomized, Double-Blind, Placebo-Controlled HOPE-3 Phase 3 Trial (n=106) Met Primary Endpoint, with Deramiocel Slowing Upper Limb Function Decline by 54 Percent versus Placebo (PUL 2.0, p=0.03) and Showing Clinically Meaningful Cardiac Benefit--
--Deramiocel BLA Remains Under Active FDA Review, with PDUFA Target Action Date of August 22, 2026--
SAN DIEGO, July 29, 2026 (GLOBE NEWSWIRE) --... More
